Clinical Trials Logo

Clinical Trial Summary

GSK189254 is a highly potent histamine 3 (H3) receptor antagonist which has demonstrated efficacy in the reduction of mechanical hyperalgesia and allodynia in the chronic constriction injury pre-clinical model of neuropathic pain (NP). The mechanism of action of GSK 189254 in the pain model is hypothesised to be via enhanced release of monoamines in the central nervous system (CNS). A similar mechanism of action has also been shown for duloxetine. In this phase I study, the safety and efficacy of GSK189254 will be investigated in the electrical hyperalgesia (EH) model in healthy volunteers to build confidence that the preclinical efficacy demonstrated by this compound will translate into patients.

This study will be conducted as a double-blind, double-dummy, placebo-controlled, incomplete block, two period crossover study. Up to 40 healthy male or female volunteers, aged 18-45 years old, will be randomised into the study in order to achieve 32 evaluable subjects. Subjects will undergo two 3-week treatment periods and will be randomised to receive placebo and either GSK189254 (up to 100µg once daily) or duloxetine (up to 60mg daily). There will be a one week washout between treatment periods. The effects of repeated oral dosing of GSK189254 and duloxetine on secondary hyperalgesia in the EH model will be determined. Subject: GSK189254, Neuropathic pain (NP), H3 antagonist, duloxetine, Electrical hyperalgesia, Phase I, Healthy volunteers, Double blind, Safety, tolerability.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00387413
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date October 2, 2006
Completion date May 31, 2007

See also
  Status Clinical Trial Phase
Completed NCT01301079 - Evaluation of the Effect of Ketamine on Remifentanil-induced Hyperalgesia Phase 3
Completed NCT00833755 - Effect of Ketamine on Opioid-Induced Hyperalgesia N/A
Completed NCT00279032 - GW406381 In Patients With Peripheral Nerve Injury Phase 1
Completed NCT03793790 - The Role of Learning in Nocebo Hyperalgesia N/A
Completed NCT03985995 - Pain Response to Cannabidiol in Induced Acute Nociceptive Pain, Allodynia and Hyperalgesia By Using a Model Mimicking Acute Pain in Healthy Adults N/A
Completed NCT04199858 - Electrophysiological Correlates of Nocebo Effects on Pain N/A
Completed NCT02938455 - DNA Methylation and Perioperative Pain Treatment
Not yet recruiting NCT02934763 - Opioid Induced Hyperalgesia (OIH) Modulation With Propranolol Phase 4
Completed NCT02653703 - L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain N/A
Completed NCT02253966 - Preoperative Intraarticular Injection of Methylprednisolone in Patients Scheduled for Total Knee-arthroplasty Phase 2
Completed NCT01702389 - Opioid-induced Hyperalgesia After Remifentanil Infusion Phase 4
Terminated NCT01615510 - Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models Phase 1
Completed NCT00218374 - Dextromethorphan, Gabapentin, and Oxycodone to Treat Opioid-Induced Hyperalgesia N/A
Completed NCT04197154 - Pain-related Fear as a Facilitator of Nocebo Hyperalgesia N/A
Completed NCT02976337 - Effect of High-dose Naloxone Following Third Molar Extraction Phase 2
Completed NCT03354624 - Cortical Neuroplasticity by Muscle Pain of Pain-induced Plasticity N/A
Completed NCT02596360 - Dextromethorphan Effect on Central Sensitization to Pain in Healthy Volunteers Phase 1
Recruiting NCT01480765 - Preventing Pain After Heart Surgery Phase 4
Recruiting NCT01015482 - The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun) Phase 4
Completed NCT01025245 - Effect of Intraoperative Magnesium on Remifentanil-induced Postoperative Hyperalgesia After Thyroidectomy Phase 4